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Abstract
Background: Age at onset of Huntington's disease (HD) is correlated with the size of the
abnormal CAG repeat expansion in the HD gene; however, several studies have indicated that
other genetic factors also contribute to the variability in HD age at onset. To identify modifier
genes, we recently reported a whole-genome scan in a sample of 629 affected sibling pairs from
295 pedigrees, in which six genomic regions provided suggestive evidence for quantitative trait loci
(QTL), modifying age at onset in HD.
Methods: In order to test the replication of this finding, eighteen microsatellite markers, three
from each of the six genomic regions, were genotyped in 102 newly recruited sibling pairs from 69
pedigrees, and data were analyzed, using a multipoint linkage variance component method, in the
follow-up sample and the combined sample of 352 pedigrees with 753 sibling pairs.
Results: Suggestive evidence for linkage at 6q23-24 in the follow-up sample (LOD = 1.87, p =
0.002) increased to genome-wide significance for linkage in the combined sample (LOD = 4.05, p
= 0.00001), while suggestive evidence for linkage was observed at 18q22, in both the follow-up
sample (LOD = 0.79, p = 0.03) and the combined sample (LOD = 1.78, p = 0.002). Epistatic analysis
indicated that there is no interaction between 6q23-24 and other loci.
Conclusion: In this replication study, linkage for modifier of age at onset in HD was confirmed at
6q23-24. Evidence for linkage was also found at 18q22. The demonstration of statistically significant
linkage to a potential modifier locus opens the path to location cloning of a gene capable of altering
HD pathogenesis, which could provide a validated target for therapeutic development in the human
patient.
Background
Huntington's disease (HD [MIM 143100]) is a progressive
neurodegenerative disorder with an age at neurological
onset commonly in midlife. The major clinical features of
HD include involuntary choreiform movements, psychi-
atric symptoms, and cognitive dysfunction [1-3]. The
genetic mutation associated with HD is located in 4p16.3
and is characterized by expansion of a CAG repeat in the
first exon of the gene encoding the huntingtin protein [4].
Many studies have examined the relationship of the CAG
repeat to neurological onset in HD, and found that its
length accounts for about 70% of the variation in age at
onset [5,6]. Our recent studies [7] and those of others
[5,6] suggest that the remaining variation in HD age at
onset is strongly heritable and about 56% [8] of the vari-
ance remaining in age at onset is attributable to genes
other than the HD gene, supporting the existence of genes
capable of modifying HD pathogenesis. Although Wexler
et al. [5] suggest that 60% of the variance may be attribut-
able to environmental factors, remarkable similarity for
onset age in monozygotic twins [3] support primarily
genetic modifiers for this trait.
Identification of genetic modifiers in HD could be of
enormous importance for defining the mechanisms that
may be capable of delaying the onset of the disorder. We
recently reported a whole-genome scan for modifiers of
age at onset for HD in 295 pedigrees containing 629 sib-
ling pairs, with six regions, 2q33, 4p16, 5q31-32, 6p22,
6q23-24, and 18q22 exhibiting LOD scores > 1.5 [8]. In
the present study, we sought to confirm our original
whole-genome scan findings by conducting a follow-up
study of the peak regions observed in the original scan
using a newly recruited expanded follow-up sample.
Methods
Subjects
Three sample sets, newly recruited (Follow-up Sample),
original (Original Sample) and combined (Combined
Sample) were used in this study. Prior to the data clean-
ing, the Follow-up Sample consists of 149 newly recruited
HD patients. Fifteen of the newly recruited siblings were
members of 12 pedigrees used in the Original Study [8].
For these individuals a single sibling was randomly
selected from the Original Study pedigree to create a sib-
ling pair for the Follow-up study. The remaining 134 new
patient samples were recruited from 61 new pedigrees.
Only 57 of the newly recruited pedigrees, with 126 sib-
lings were kept after removing three apparently identical
twin pairs and one pair lacking onset information. Thus,
the final Follow-up Sample contained 69 pedigrees (12
original and 57 newly recruited) with 141 (15 + 126)
newly recruited subjects and 102 sibling pairs (Table 1).
The Original Sample, used in the genome scan paper [8],
consisted of 295 pedigrees with 629 sibling pairs. The
Original Sample contained 20 unaffected parents and 9
unaffected siblings to increase precision in the estimation
of identity by descend [8]. The Combined Sample, con-
sisting of both the Original Sample and the Follow-upBMC Medical Genetics 2006, 7:71 http://www.biomedcentral.com/1471-2350/7/71
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Sample, had 352 pedigrees with 836 HD subjects. Twenty-
one new sibling pairs and one half sib-pair were created
when new siblings were added to existing pedigrees for a
total of 753 sibling pairs in the Combined Sample (Table
1).
Age at onset
Age at onset, defined as the onset of motor impairment,
was reported for all affected participants [9,10]. Cases
with 36 or more repeats, were designated HD mutation
carriers in accordance with published associations with
disease expression [11]. The quantitative trait utilized in
linkage analysis was adjusted for the effects of the CAG
repeat expansion using two different regression models.
Both models used the logarithmically transformed age at
onset as the dependent variable. The first model (Model
One) adjusted only for the size of the expanded CAG
repeat [log(onset) = α + β(HD)CAG]. The second model
(Model Two), that we had used in our original genome
scan [8] and previously described [7], adjusted for the HD
repeat, the normal repeat and their interaction [log(onset)
= α + β1(HD)CAG + β2(Normal)CAG + β3(HD)CAG ×
(Normal)CAG]. Random effect models (Proc MIXED in
SAS) were used in these models to account for familial
clustering. Each model was used to determine the
expected age at onset for a given expanded CAG repeat,
and the residual was computed as the difference between
the observed and expected age at onset. Residuals were
standardized to a mean of zero and a standard deviation
of 1. Both models show similar modest negative skew-
ness. The skewness of the residual generated by Model
One is -0.42 and the kurtosis is 1.82. Corresponding val-
ues for Model Two were -0.49 and 1.11, respectively.
Residual onset ages for all analyses were computed using
the 836 combined sample plus 234 locally studied HD
patients recruited from the New England HD Research
Center and 303 brain specimens from the McLean Brain
Tissue Resource Center, for a total sample of 1373. While
the local and brain samples are not included in this link-
age analysis, they provide an additional randomly ascer-
tained samples to more accurately model the relationship
between age at onset and CAG repeat sizes. Finally,
because our future studies will involve SNP association
studies in all of three samples (HD MAPS families, the
locally collected DNAs, and the brain specimens), we
sought to define the repeat adjusted age at onset uni-
formly across all three samples.
The heritability analyses were conducted using maximum
likelihood procedures as implemented in the SOLAR pro-
gram [12].
CAG repeat size determination
HD  CAG repeat sizes were determined by polymerase
chain reaction using an assay that does not include the
adjacent proline (CCG) repeat. Cases with 36 or more
repeats were designated HD mutation carriers.
Genotyping
All the newly recruited HD samples were genotyped by
three microsatellite markers at each of the six regions with
maximum multipoint LOD scores greater than or equal to
1.5 in the original genome scan [8]. The markers at each
locus comprised the peak marker and the two markers
from the original scan that flank it (see Table 2). Prior to
the analysis, the sib_kin program in the ASPEX package
[13] was used to verify sibling relationships. Mendelian
inconsistencies were then identified using INFER, in the
PEDSYS package [14] and MERLIN [15]. Genotypes for
the entire nuclear family were deleted for the particular
marker when an inconsistency was detected. The genotyp-
ing data set was 93% complete, with 7% genotyping fail-
ure or error rate.
Linkage analysis
Variance component linkage analysis to repeat adjusted
age at onset was performed using MERLIN [15]. We per-
formed multipoint linkage analysis in the Original 295
pedigrees, the Follow-up 69 pedigrees, and the Combined
352 pedigrees. Adjusted age at onset was available for all
HD affected participants. Age at onset was coded as "miss-
ing" for all unaffected individuals.
The oligogenic linkage analysis and epistatic interaction
analysis were performed by the SOLAR program [12].
MERLIN was used to generate the IBD estimates and these
were converted into SOLAR format for analyses. The via-
bility of epistatic model was tested. The interaction term
was constrained to non-interaction, and then the differ-
ence between interaction and non-interaction models was
tested by chi-square.
Results
Three sample sets, newly recruited (Follow-up Sample),
original (Original Sample) and combined (Combined
Sample) were used in this study. The Original, Follow-up
and Combined samples are described in Table 1. The
mean age at onset is similar for the Follow-up (range 17
to 70 y) and Original samples (range 9 to 82 y). All three
samples exhibited strong heritability estimates. The herit-
ability estimates (h2 ± SE) for expanded repeat adjusted
age at onset (Model One) are 0.72 ± 0.09 for the Original
Sample, 0.74 ± 0.20 for the Follow-up Sample and 0.74 ±
0.08 for the Combined Sample.
Multipoint linkage analyses were completed using both
Model One, adjusting for expanded HD repeats only, andBMC Medical Genetics 2006, 7:71 http://www.biomedcentral.com/1471-2350/7/71
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Model Two, adjusting for expanded HD repeats, normal
repeats and their interactions. Multipoint LOD scores
obtained in these three sample sets for the six chromo-
some regions (2q33, 4p16, 5q31-32, 6p22, 6q23-24, and
18q22) are presented in Table 3 and Figure 1. For the Fol-
low-up Sample, the highest LOD score was observed at the
6q23-24 region (LOD = 1.87, p = 0.002, Model One; or
LOD = 2.27, p = 0.0006, Model Two). One additional
region provided modest confirmation for linkage, 18q22
(LOD = 0.79, p = 0.03, Model One; or LOD = 0.79, p =
0.02, Model Two). However, no evidence for linkage was
seen at 2q33 (LOD = 0.17, p = 0.2, Model One; LOD =
0.21, p = 0.2, Model Two), 4p16 (LOD = 0.0, p = 0.5,
Model One and Model Two), 5q31-32 (LOD = 0.15, p =
0.2, Model One; LOD = 0.12, p = 0.2, Model Two), and
6p22 (LOD = 0.01, p = 0.4, Model One and Model Two).
Model One analysis in the Combined Sample yielded sig-
nificant linkage at 6q23-24 (LOD = 4.05, p = 0.00001)
and suggestive linkage at 4p16 (LOD = 1.94, p = 0.0014)
and 18q22 (LOD = 1.78, p = 0.002). The 2q33 (LOD =
1.37, p = 0.006) and 6p22.3 (LOD = 1.14, p = 0.011)
regions achieved a LOD score greater than 1.0. However,
the LOD score at 5q31-32 dropped to 0.98 (p = 0.02). The
Model Two analysis, adjusting for the expanded repeat,
normal repeats and their interaction, generated higher
LOD scores than Model One at 6q23-24 in all the three
tested sample sets: the Original Sample (LOD = 3.5, p =
0.00003), Follow-up Samples (LOD = 2.27, p = 0.0006)
and Combined Sample (LOD = 4.94, p < 10-6). All of the
other analyses using Model Two produced LOD scores
very similar to those of Model One. Epistatic analysis indi-
cated that there is no interaction between 6q23-24 and
five other loci.
Discussion
The purpose of this study was to replicate our original
linkage findings for repeat adjusted age at onset in HD [8]
in an expanded sample. A p value of 0.01 is needed to con-
firm evidence for linkage [16]. In this Follow-up study,
strong evidence for linkage was observed at 6q23-24 (p =
0.002) and suggestive support for linkage was observed at
18q22 (p = 0.03). No evidence for linkage was observed in
the Follow-up Sample at 2q33 (p = 0.2), 4p16 (p = 0.5),
5q31-32 (p = 0.2) and 6p22.3 (p = 0.4). The lack of con-
firmation for the latter four loci may indicate that these
regions do not contain genes that modify the age at neu-
rologic onset for HD or that this relatively small Follow-
up study did not adequately sample families which carry
modifier genes from these regions.
In the Combined Sample, the Model One analysis, adjust-
ing only for the size of the expanded repeat, yielded signif-
icant linkage at 6q23-24 (LOD = 4.05, p = 0.00001). The
Model Two analysis, adjusting for the expanded repeat,
normal repeats and their interaction, generated higher
LOD score than Model One at 6q23-24. The LOD scores
of the Original Sample (LOD = 3.5, p = 0.00003), Follow-
up Samples (LOD = 2.27, p = 0.0006) and Combined
Sample (LOD = 4.94, p < 10-6) are highly significant using
this second model. All of the other analyses using Model
Two produced LOD scores very similar to those of Model
One. We emphasize results from Model One because beta
coefficients from Model Two show greater variability
compared with those computed in the original scan [8].
Changes in the composition of the sample have modified
the relationship of the repeat sizes to onset age from that
seen in the original sample alone [8]. Although all three
terms in the model (HD repeat, normal repeat and the
interaction of these) are significant predictors of age at
onset, the sign of the beta coefficients were opposite to
those seen in the original scan [8] for the normal repeat
and interaction terms. Consequently, the Model Two
adjustment may be susceptible to as yet unidentified sam-
ple stratification effects or over-specification of the model.
The results of the Combined Sample are generally similar
to those of the original genome scan (see Table 3). Signif-
icant evidence for linkage was observed at 6q23-24 in the
Combined Sample (LOD = 4.05, p  = 0.00001). We
reported a LOD score of 2.28 at 6q23-24 in our original
genome scan [8], while the same sample generates a LOD
score of 3.5 (p = 0.00003) in the current study using the
same model (Model Two). The difference is due to a mod-
Table 1: The Study Subjects.
Original Sample Follow-up Sample Combined Sample
Pedigrees 295 69a 352
Sibling-pairs 629 102 753b
Patients 695 141 836
Mean Onset ± SD 39.3 ± 12.1 39.2 ± 11.8 39.3 ± 12.0
Mean HD repeat ± SD 46.4 ± 5.9 45.5 ± 5.5 46.2 ± 5.7
Note (details provided in Subjects section of Materials and Methods):
a 57 pedigrees are newly recruited, and the remaining 12 are from the Original Sample with newly recruited siblings.
b The number of pairs in the Combined Sample exceeds that for the sum of the Original Sample and Follow-up Sample because additional sibling 
pairs (21 new sibling pairs and one half sib) were created when new siblings were added to existing pedigrees.BMC Medical Genetics 2006, 7:71 http://www.biomedcentral.com/1471-2350/7/71
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ification of the method used to define the repeat adjusted
age at onset. In the original genome scan only the 754
individuals were used to model the relationship of repeat
size age at onset. In the present study, we used a sample of
1373 individuals, derived from the 836 in the combined
sample, plus 234 locally studied HD affected persons and
a sample of 303 brain specimens. While the local and
brain samples do not represent sib-pairs that could be
included in this linkage analysis, they provide additional
randomly ascertained samples to more accurately model
the relationship between age at onset and CAG repeat
sizes. They also provide an increased sample size for sub-
sequent fine-mapping association studies to assess candi-
date modifiers. The increased sample size provided a
more accurate assessment of the relationship between
repeat size and age at onset, yielding a residual that more
accurately adjusts for the effect of repeat size on age at
onset in HD.
In addition to the 6q23-24 peak, the Follow-up study sup-
ports evidence for linkage at 18q22 (LOD = 0.79, p = 0.03,
Model One; LOD = 0.79, p = 0.02, Model Two). The Com-
bined Sample provides suggestive evidence for linkage at
this locus (LOD = 1.78, p = 0.002, Model One; LOD =
1.55, p = 0.004, Model Two). Suggestive linkage is still
observed at 4p16 (LOD = 1.94, p = 0.0014, Model One;
LOD = 1.9, p = 0.002, Model Two) in the Combined Sam-
ple, although, this locus was not confirmed in the Follow-
up study and the LOD score is lower than that of the orig-
inal scan (LOD = 2.19, p = 0.0007, Model One; LOD =
2.15, p = 0.0008, Model Two). The decreased LOD score
at 4p16 may be a consequence of genetic heterogeneity,
possibly reflecting the diverse ethnic background of the
sample [17].
The epistatic analysis indicated that there is no interaction
between 6q23-24 with five other loci. Therefore, we
Table 2: Eighteen microsatellite markers genotyped, three at each of the six loci, for Follow-up study. Marker 2 is the peak marker in 
original study at each locus.
Chromosome Marker 1 Position (cM) Marker 2 Position (cM) Marker 3 Position (cM)
2q33 D2S1391 186 D2S1384 200 D2S2944 210
4p16 D4S3360 0 D4S2366 13 D4S403 26
5q31-32 D5S816 139 D5S1480 147 D5S820 160
6p22.3 D6S1006 27 D6S1959 34 D6S2439 42
6q23-24 D6S1009 138 GATA184A08 146 D6S2436 155
18q22 D18S851 75 D18S858 80 D18S1357 89
Table 3: Multipoint LOD score and chromosomal location in the Original, Follow-up and Combined samples are shown.
A Model One LOD scores.
Chromosome Location Original Sample Follow-up Sample Combined Sample
Distance *
(cM)
LOD p-value Distance *
(cM)
LOD p-value Distance *
(cM)
LOD p-value
2q33 200 1.37 0.006 210 0.17 0.2 200 1.37 0.006
4p16 2 2.19 0.0007 0 0 0.5 0 1.94 0.0014
5q31-32 147 1.23 0.009 160 0.15 0.2 142 0.98 0.02
6p22.3 34 1.13 0.011 34 0.01 0.4 34 1.14 0.011
6q23-24 149 2.75 0.0002 142 1.87 0.002 149 4.05 0.00001
18q22 89 1.23 0.009 75 0.79 0.03 89 1.78 0.002
B Model Two LOD scores.
2q33 200 1.56 0.004 210 0.21 0.2 200 1.62 0.003
4p16 2 2.15 0.0008 0 0 0.5 0 1.9 0.002
5q31-32 147 1.27 0.008 160 0.12 0.2 147 0.98 0.02
6p22.3 34 0.88 0.02 34 0.01 0.4 34 0.95 0.02
6q23-24 148 3.5 0.00003 142 2.27 0.0006 149 4.94 <10-6
18q22 89 0.96 0.02 75 0.79 0.02 89 1.55 0.004
A. Model One was used to adjust age at onset and age at onset was adjusted by HD repeats only; B. Model Two was used to adjust age at onset, and 
age at onset was adjusted by HD repeat, normal repeat and their interaction.
* The genetic distances are as indicated by the Marshfield linkage map [26]BMC Medical Genetics 2006, 7:71 http://www.biomedcentral.com/1471-2350/7/71
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assumed that the potential modifiers are not members in
a common pathway. The 1-LOD unit support interval
(133 – 153 Mb) at 6q23-24 contains 128 known and pre-
dicted genes (Ensembl v27) [18]. Two genes of particular
interest are serum and glucocorticoid regulated kinase
(SGK, 135 Mb) and metabotropic glutamate receptor 1
(GRM1, 146 Mb). A recent study reported that SGK levels
are increased in brains of HD patients; SGK phosphor-
ylates huntingtin at serine 421, protecting striatal neurons
against toxicity caused by a polyQ-huntingtin amino-ter-
minal fragment [19]. SGK is a plausible candidate gene.
GRM1  is located within 2 Mb of the peak marker
(GATA184A08, 148 Mb) and is highly expressed in the
cerebellum [20]. One prominent action of GRM1 is to
protect neurons from apoptotic death [21]. In addition,
several studies reported that GRIK2  is associated with
early onset [22,23]. GRIK2 (6q16.3, 102 Mb) is about 30
Mb proximal to the 1-LOD interval on the confirmed
6q23-24 (133 – 153 Mb). However, the variance in onset
age explained by GRIK2 is small and one would not expect
that it would be detected by linkage. The 7-Mb 1-LOD
unit support interval (50 – 57 Mb) at 18q22 contains 36
known genes, according to the Ensembl database (v27)
[18]. Interesting candidate genes in this interval include
NEDD4L (18q21, 54 Mb), which encodes a neural precur-
sor cell expressed, developmentally down-regulated 4-like
gene. NEDD4L is an ubiquitin ligase and contains WW
domains. Yeast two-hybrid studies found that huntingtin
binds to a group of genes with WW domains [24]. One of
the interesting features of NEDD4L is that it may mediate
degradation of the product of SGK, the above mentioned
candidate gene located at 6q23 [25].
Conclusion
In conclusion, this replication study confirms evidence for
linkage in the 6q23-24 region observed in our original
genome scan. Although the other regions, particularly
18q22, may also contain genes that modify age at onset in
HD, the 6q23-24 shows evidence for harboring one or
more genetic modifiers that exceeds the level required for
genome-wide statistical significance (LOD >3.6) [16]. In
our approach, a genetic modifier of HD is a gene that is
inherently capable of modifying the course of disease
pathogenesis, thereby altering the observed age at onset.
Multipoint linkage results generated by MERLIN across six chromosome regions in followup study Figure 1
Multipoint linkage results generated by MERLIN across six chromosome regions in followup study. The x-axis indicates genetic 
distance and the y-axis indicates LOD score. These data show the confirmed evidence for linkage to 6q23-24 using Model One 
age at onset adjustment.
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Consequently, identifying such genetic modifiers is a
potential route to validated targets for therapeutic devel-
opment aimed at delaying or preventing neurological
onset in HD. We present evidence that the 6q23-24 region
contains such a genetic modifier, which opens the way for
its identification and eventual exploitation for treatment
of this devastating disorder.
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